Pharmaceutical News and Articles

SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition

DUBLIN, Calif., December 02, 2008 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th American Society of Hematology (ASH) Annual Meeting & Exposition on December 7 and 8, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: SGI-1776, SGI-1252, and SGI-110. All presentations will occur as poster presentations.

 

                        Abstract Number/Title                   Date
    Abstract 1922: Inhibiting PIM-1 is Effective in Vitro
    and in Vivo against ALL: A Novel Mechanistic and
    Potentially Clinically Relevant Druggable Target            Dec 7

    Abstract 2629: Preclinical Characterization of the
    JAK-2 Inhibitor, SGI-1252                                   Dec 7

    Abstract 3355: Anti-AML Activity of Combined Epigenetic
    Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036
    and Histone Deacetylase Inhibitor Panobinostat              Dec 8

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

 

     Contacts:

     SuperGen, Inc.                   Dorland Global Public Relations
     Timothy L. Enns                  Michael Beckerich (Media)
     SVP, Corporate Communications    Tel: (212) 677-7632
     & Business Development           mbeckerich@dorland.com
     Tel: (925) 560-2810
     Email: tenns@supergen.com

CONTACT: Timothy L. Enns, SVP, Corporate Communications & BusinessDevelopment of SuperGen, Inc., +1-925-560-2810, ; orMedia, Michael Beckerich for SuperGen, Inc., +1-212-677-7632, tenns@supergen.com mbeckerich@dorland.com

Web site: http://www.supergen.com/

Ticker Symbol: (NASDAQ-NMS:SUPG)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Clinical Trial Results...

Clinical Trial Results Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

MedNotes
Advertisement

(web9)